International CIPN Assessment and Validation Study (ICAVS)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04633655 |
Recruitment Status :
Recruiting
First Posted : November 18, 2020
Last Update Posted : May 25, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Chemotherapy-induced Peripheral Neuropathy Quality of Life | Other: outcome measures for CIPN testing |
Study Type : | Observational |
Estimated Enrollment : | 1000 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | International Chemotherapy Induced Peripheral Neurotoxicity (CIPN) Assessment and Validation Study |
Actual Study Start Date : | June 8, 2020 |
Estimated Primary Completion Date : | May 1, 2024 |
Estimated Study Completion Date : | October 1, 2025 |
Group/Cohort | Intervention/treatment |
---|---|
Patients who are receiving a neurotoxic chemotherapy
List of neurotoxic drugs eligible for enrolment
|
Other: outcome measures for CIPN testing
questionnaires administration, physician based scales for CIPN data collection |
- Chemotherapy-induced peripheral neurotoxicity as assessed by change in NCI-CTC v.5 sensory and motor grade [ Time Frame: 5 YEARS ]NCI-CTC v.5 sensory and motor (changes from base line to end treatment of a 0-5 score)
- Chemotherapy-induced peripheral neurotoxicity as assessed by change in PRO-CTCAE [ Time Frame: 5 YEARS ]PRO-CTCAE (changes from base line to end treatment of a 0-5 score for each item)
- Chemotherapy-induced peripheral neurotoxicity as assessed by change in Pain Intensity Numerical Rating Scale (PI-NRS) [ Time Frame: 5 YEARS ]difference between baseline and end of treatment of chemotherapy-induced peripheral neurotoxicity as assessed by change in Pain Intensity Numerical Rating Scale (PI-NRS) (0-10 score).
- Chemotherapy-induced peripheral neurotoxicity as assessed by change in NPS-CIN scale [ Time Frame: 5 YEARS ]difference between baseline and end of treatment of chemotherapy-induced peripheral neurotoxicity as assessed by change in NPS-CIN (changes from base line to end treatment of a 0-10 score)
- Chemotherapy-induced peripheral neurotoxicity as assessed by change in EORTC CIPN20© scale [ Time Frame: 5 YEARS ]difference between baseline and end of treatment of chemotherapy-induced peripheral neurotoxicity as assessed by change in EORTC CIPN20© (changes from base line to end treatment of a 0-100 score)
- Chemotherapy-induced peripheral neurotoxicity as assessed by change in FACT-GOG NTX v.4© scale [ Time Frame: 5 YEARS ]difference between baseline and end of treatment of chemotherapy-induced peripheral neurotoxicity as assessed by change in FACT-GOG NTX v.4© (changes from base line to end treatment of a 0-44 score)
- Chemotherapy-induced peripheral neurotoxicity as assessed by change in TNSn© scale [ Time Frame: 5 YEARS ]difference between baseline and end of treatment of chemotherapy-induced peripheral neurotoxicity as assessed by change in TNSn© (changes from base line to end treatment of a 0-20 score)
- Chemotherapy-induced peripheral neurotoxicity as assessed by change in PGIC scale [ Time Frame: 5 YEARS ]difference between baseline and end of treatment of chemotherapy-induced peripheral neurotoxicity as assessed by change in PGIC (changes from base line to end treatment of a 0-10 score)
- Chemotherapy-induced peripheral neurotoxicity as assessed by change in OXA-NQ scale [ Time Frame: 5 YEARS ]difference between baseline and end of treatment of chemotherapy-induced peripheral neurotoxicity as assessed by change in OXA-NQ (changes from base line to end treatment of number of symptoms: this is a yes/no questionnaire for the presence of neuropathy symptoms)
- Chemotherapy-induced peripheral neurotoxicity as assessed by change in EORTC CIPN15 scale [ Time Frame: 7 YEARS ]difference between baseline and end of treatment of chemotherapy-induced peripheral neurotoxicity as assessed by change in EORTC CIPN15 (changes of the global score of this questionnaire, 0-60)
- Chemotherapy-induced peripheral neurotoxicity as assessed by change in TNSc© scale [ Time Frame: 7 YEARS ]difference between baseline and end of treatment of chemotherapy-induced peripheral neurotoxicity as assessed by change in TNSc© (changes of the global score of this physician base scale ranging 0-48)
- Chemotherapy-induced peripheral neurotoxicity as assessed by change in nerve conduction studies [ Time Frame: 7 YEARS ]difference between baseline and end of treatment of chemotherapy-induced peripheral neurotoxicity as assessed by change in nerve conduction study of the radial (motor and sensory), ulnar (motor and sensory), sural, dorsal sural and common peroneal nerves. Amplitude (microV for sensory and mV for motor recordings) and velocity (m/sec) will be obtained. A decrease under the normative values at all time points respect to base line will be considered as sign of neuropathy.
- Chemotherapy-induced peripheral neurotoxicity as assessed by change in Quantitative sensory testing (QST) [ Time Frame: 7 YEARS ]difference between baseline and end of treatment of chemotherapy-induced peripheral neurotoxicity as assessed by change in QST: scores in seconds for time to pain onset and pain intensity (0=no pain; 10=worst pain
- Chemotherapy-induced peripheral neurotoxicity as assessed by change in neurofilament light chain (NfL) levels [ Time Frame: 7 YEARS ]difference between baseline and end of treatment of chemotherapy-induced peripheral neurotoxicity as assessed by change in Serum for biomarkers search: NfL dosage (pg/mL)
- Chemotherapy-induced peripheral neurotoxicity as assessed by change in DN4 scale [ Time Frame: 7 YEARS ]difference between baseline and end of treatment of chemotherapy-induced peripheral neurotoxicity as assessed by change in DN4 (this is a scale ranging 0-10)
Biospecimen Retention: Samples Without DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria
Subjects must meet all of the following inclusion criteria to be eligible for enrolment into the study:
- Subjects must be candidates for neurotoxic chemotherapy at doses expected to be potentially neurotoxic (a list of neurotoxic drugs is provided in Appendix 1).
- Male and female subjects who are 18 years of age or older.
- Subjects freely provide informed consent by signing and dating an informed consent form prior to study entry.
- Subjects must be willing to complete all study-related activities and follow-up visits required by the protocol.
- Subjects must have a Karnofsky performance score greater than or equal to 70. Exclusion Criteria
Subjects presenting with any of the following will not be included in the study:
- Poor prognosis, with high probability to be unable to complete the planned chemotherapy treatment.
- Concomitant neurologic conditions (e.g., brain tumor, spinal or brain metastases) that would interfere or complicate the assessments.
- Severe depression that in the opinion of the Investigator would complicate the assessments.
- Chronic treatment with antiepileptic drugs, antidepressants and major analgesics, unless stable dosing and conditions have been reached for 3 months prior to entry.
- Preventive interventions (e.g., antioxidants, cryotherapy, distal pressure).
- Subjects who are currently receiving another medication other than antineoplastic chemotherapy drugs that has known potential to produce neurologic peripheral nerve toxicity (e.g. metronidazole, isoniazid, amiodarone, antiretroviral medications).
- Subjects with any other condition, which, in the investigator's judgment, might decrease the chance of obtaining satisfactory data to achieve the objectives of the study.
- Previous neurotoxic chemotherapy.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04633655
Contact: GUIDO CAVALETTI, MD | + 39 02 6448 8039 | guido.cavaletti@unimib.it | |
Contact: PAOLA ALBERTI, MD, PhD | +39 02 6448 8154 | paola.alberti@unimib.it |
Study Chair: | GUIDO CAVALETTI, MD | University of Milano Bicocca | |
Principal Investigator: | PAOLA ALBERTI, MD | University of Milano Bicocca |
Responsible Party: | University of Milano Bicocca |
ClinicalTrials.gov Identifier: | NCT04633655 |
Other Study ID Numbers: |
ICAVS |
First Posted: | November 18, 2020 Key Record Dates |
Last Update Posted: | May 25, 2023 |
Last Verified: | May 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
clinimetrics biomarker PRO outcome measures |
Peripheral Nervous System Diseases Neuromuscular Diseases Nervous System Diseases |